Regulatory · source year

2009 regulatory records

7 selected, source-linked regulatory records dated 2009. This is selective source coverage, not a complete timeline.

Dated records

7 selected records.

Peptide profiles

7 connected profiles.

Cited sources

7 distinct public records.

Cited chronology

Dated source records

All record types in 2009 →

December 2009

1 record

Desmopressin

Federal Register notice E9-28593

The Federal Register published notice E9-28593, attributed to FDA and its parent HHS department, on 2009-12-01. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

October 2009

1 record

June 2009

2 records

Leuprolide

Federal Register notice E9-13272

The Federal Register published notice E9-13272, attributed to FDA and its parent HHS department, on 2009-06-08. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

May 2009

1 record

Oxytocin + 1 more

Federal Register notice E9-11628

The Federal Register published notice E9-11628, attributed to FDA and its parent HHS department, on 2009-05-19. Its official title is “Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin and Sermorelin.

Source: Federal Register via GovInfo ↗

→

March 2009

2 records

Liraglutide

Federal Register notice E9-5024

The Federal Register published notice E9-5024, attributed to FDA and its parent HHS department, on 2009-03-10. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

Source: Federal Register via GovInfo ↗

→